|
|||||||||||||||||
|
|||||||||||||||||
|
|
|||||||||||||||||
|
| More Health News
|
News--
BOSTON (Reuters) -
Taking a baby aspirin may prevent heart
attacks in men, but it does little to ward off a first heart
attack in women aged 45 to 64, researchers reported Monday.
However, the low-dose aspirin therapy widely recommended
for both men and women may reduce the risk of stroke caused by
a blocked blood vessel in the brain, according to the findings.
The results do not apply to people who are taking aspirin
because they have already survived a heart attack.
Until now, doctors have widely recommended low-dose aspirin
therapy for both genders, even though that advice was based on
studies that mostly included men.
But when researchers tested aspirin on nearly 40,000 women
as part of the Women's Health Study, they found the women who
received a placebo were no more likely to have a first heart
attack than those who regularly took aspirin for 10 years.
"Aspirin had no significant effect on the risk of fatal or
nonfatal myocardial infarction (heart attack)," said the team,
led by Paul Ridker of Brigham and Women's Hospital in Boston.
But women who took 100 milligrams of aspirin every other
day -- the equivalent of taking one baby aspirin each day --
were 24 percent less likely to have an ischemic stroke, the
most common type of stroke caused when blood can't get to the
brain.
That benefit came with a price.
The women who were taking aspirin were 40 percent more
likely to develop serious stomach or intestinal bleeding that
required a transfusion.
Among the 4,097 women in the study over 64, regular aspirin
use began to show a clear benefit, cutting the risk of ischemic
stroke by 30 percent and the chance of heart attack by 34
percent.
"Age significantly modified the effect of aspirin," the
researchers said.
Previous research on men showed regular aspirin use reduced
the risk of having a heart attack by 32 percent, yet did not
seem to affect the likelihood of a stroke.
Ridker and his colleagues said the findings "clearly
demonstrate the importance of studying women as well as men in
major cardiovascular clinical trials."
The study, which will be published later this month in The
New England Journal of Medicine (news - web sites), was released early to coincide
with a presentation at a meeting of the American College of
Cardiology.
|
|
|||
|
Home |
About ActiveHerb |
Contact Us |
Privacy Policy |
Affiliate Program |
Wholesale Order Help: Ways to order | Mail order | 邮购 | Shipping Cost | Return Policy | International Order | Order FAQ |
|||
|
(C) 2003-2008, ActiveHerb Technology, Inc. All rights reserved.
|
|||
|
† These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure or prevent any disease.
Contents in www.activeherb.com is for information purpose only and are written to our best knowledge
and expertise for the scientific accuracy. They are not to replace the advice of your physicians.
The research cited in our contents are published in scientific journals and have not
subjected to the FDA evaluation. We reserve the copyright to protect our contents. Any reproduction without in its
entirety and without explicit credits to ActiveHerb is prohibited.
|